<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577367</url>
  </required_header>
  <id_info>
    <org_study_id>2015-05-02</org_study_id>
    <nct_id>NCT02577367</nct_id>
  </id_info>
  <brief_title>Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding</brief_title>
  <official_title>The Effect of Holding Tube Feeding When Administering Levothyroxine on the Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jocelyne Karam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to describe the changes in Levothyroxine dosage requirements in patients with&#xD;
      hypothyroidism started on enteral feeding, and assess whether giving levothyroxine on empty&#xD;
      stomach affects the mean percentage increase expected in Levothyroxine dosage in these&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a Randomized Controlled trial comparing the mean percentage of&#xD;
      Levothyroxine dosage change in hypothyroid patients after the starting of enteral feeding in&#xD;
      an inpatient setting in two different groups: a control group where Levothyroxine will be&#xD;
      administered with continuous enteral nutrition, and an intervention group where enteral&#xD;
      nutrition will be held for two hours before and two hours after the Levothyroxine&#xD;
      administration.&#xD;
&#xD;
      The enrollment of eligible patients will be over two to three years and follow up will&#xD;
      continue for the duration of the hospital stay or 12 weeks, which ever occurs earlier.&#xD;
      Eligible patients will have thyroid function tests at enrollment (within three days of the&#xD;
      starting of the tube feeding) and afterwards weekly. Levothyroxine dosage will be adjusted by&#xD;
      the endocrinology research team according to the thyroid function results. Initial&#xD;
      Levothyroxine dosage and subsequent dosages will be recorded and the mean percentage decrease&#xD;
      or increase of Levothyroxine dosage required will be measured in each group. An eventual&#xD;
      difference between the two groups mean percentage change will be tested for statistical&#xD;
      significance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lost interest in current study&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">April 8, 2020</completion_date>
  <primary_completion_date type="Actual">April 8, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage change of Levothyroxine dosage</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Primary outcome will be the measurement of the mean percentage change of levothyroxine dosage ( end of the enrollment dose as compared to baseline dose) in each of the two comparative groups: The control group of patients receiving Levothyroxine during the tube feeding, and the intervention group of patients receiving Levothyroxine on empty stomach (two hours before and two hours after holding the feeding)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Levothyroxine on empty stomach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levothyroxine during feeding</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levothyroxine will be given while the enteral feeding is running</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Administer Levothyroxine</description>
    <arm_group_label>Levothyroxine during feeding</arm_group_label>
    <arm_group_label>Levothyroxine on empty stomach</arm_group_label>
    <other_name>Synthroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults admitted to Maimonides Medical Center&#xD;
&#xD;
          -  Started on Enteral feeding within 3 days of enrollment: tube feeding, Percutaneous&#xD;
             Endoscopic Gastrostomy or PEG tube feeding, or Jejunostomy tube feeding.&#xD;
&#xD;
          -  History of Hypothyroidism on a stable dose of Levothyroxine for at least four weeks&#xD;
             prior to enteral feeding&#xD;
&#xD;
          -  TSH 0.2-10 mIU/ml at enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant administration of medications that affect thyroid function test including&#xD;
             Cholestyramine, Sucralfate, Amiodarone, Lithium, Dopamine, Dobutamine and Dilantin at&#xD;
             enrollment.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known untreated disease or surgery of the small intestine specifically the Jejenum.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jocelyne Karam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Jocelyne Karam</investigator_full_name>
    <investigator_title>Director, Division of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Hypothyroidism</keyword>
  <keyword>Tube Feeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

